Fertilix Supplements and Assisted Reproductive Technology

Launched by UNIVERSITY REPRODUCTIVE ASSOCIATES · Dec 1, 2015

Keywords

ClinConnect Summary

No description provided

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Males with a sperm sample containing 8-OHdG levels \> 15% and must be capable of producing an ejaculate containing \>10million sperm upon study enrollment.
• • Male is between 20-55 years of age seeking treatment for infertility with his partner at URA and who is a candidate for an IUI, IVF or IVF-ICSI (excluding donor egg) procedure.
• • Female is between 20-42 years of age
• • Female exhibits tubal patency on hydrosonogram or hysterosalpingogram (HSG)
• • Female exhibits normal uterine cavity by hysteroscopy, hydrosonogram or hysterosalpingogram (HSG).
• • Exclusion Criteria
• • Subjects with initial semen analysis of an ejaculate containing \< 10 million sperm.
• • Men who have been taking nutraceuticals, vitamins or other compounds known to have antioxidant activities within4 weeks of the study. No other supplements may be taken with Fertilix.
• • Men who have hypersensitivity or an allergy to any of the ingredients in Fertilix®.
• • Men who have been treated with a chemotherapeutic agent known to cause sterility, such as cyclophosphamide.
• • Men who have taking anabolic steroids or testosterone replacement within 4 months of the study.
• • Men currently being treated with a Ca++ channel blocker or other medical treatment known to adversely affect sperm production or function.
• • Men with HIV, hepatitis B and C.